Table 2. Drug dose modification.
| Characteristics | Subgroups | N (%) |
|---|---|---|
| Dose reduction | EGFR-TKI | 0/44 (0.0) |
| MET-TKI | 6/44 (13.6) | |
| Drug discontinuation | Both drugs | 13/44 (29.5) |
| MET-TKI only | 10/44 (22.7) | |
| Cause of discontinuation of both drugs | Pneumonitis | 9/13 (69.2) |
| Hypersensitivity | 2/13 (15.4) | |
| Mediastinitis | 1/13 (7.7) | |
| Recurrent cellulitis | 1/13 (7.7) | |
| Cause of discontinuation of MET-TKI | Hypersensitivity | 5/10 (50.0) |
| Generalized pain | 2/10 (20.0) | |
| Hepatitis | 2/10 (20.0) | |
| Deep vein thrombosis | 1/10 (10.0) | |
| Discontinuation rate per drug |
EGFR-TKI | |
| • 1st or 2nd generation | 4/9 (44.4) | |
| • 3rd generation | 19/35 (54.3) | |
| MET-TKI | ||
| • Savolitinib | 19/31 (61.3) | |
| • Crizotinib | 3/11 (27.3) | |
| • Capmatinib | 1/2 (50.0) |
TKI, tyrosine kinase inhibitor.